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In a cell culture system, the three
compounds were found to increase
the amount and activity of b-hexosa-
minidase in fibroblasts obtained from
patients with ISD and ATSD. Analysis
of the mode of action of the inhibitors
revealed that they most likely function
by stabilizing the enzyme, and thus
qualify to be called pharmacological
chaperones. Interestingly, the ob-
served increase in activity (3-fold in
the best case) would be predicted to
confer sufficient function to have
beneficial effects in patients, making
them good candidates for the devel-
opment of clinically useful drugs. The
three novel pharmacological chaper-
ones displayed better selectivity pro-
files than the known b-hexosamini-
dase inhibitor that was previously
shown to have pharmacological chap-
erone activity [8], leading to the hope
that they could have fewer undesirable
off-target effects. Also of significant
interest, some of the identified com-
pounds share chemical scaffolds with
drugs that have already been ap-
proved by the FDA, increasing the like-
lihood that they could meet the criteria
for good drug candidates.
In addition to identifying novel phar-
macological chaperones with thera-
peutic potential for the treatment of
Tay-Sach diseases, the present study
represents a proof of principle that
high-throughput assays can be used
to identify new chemical entities with
pharmacological chaperone activity—
a path that will undoubtedly be fol-
lowed by investigators in search of
novel therapeutic avenues for treating
conformational diseases. Although
the present screening campaign was
searching for inhibitors, there are no
a priori theoretical reasons why other
types of ligands (agonists, allosteric
regulators, etc.) that bind and stabilize
misfolded proteins could not also
act as pharmacological chaperones.
Thus, high-throughput screens based
on the ability of compounds to restore
normal subcellular targeting, indepen-
dent of their intrinsic signaling activi-
ties, are also likely to be carried out in
the near future.
Upcoming and ongoing clinical trials
for Tay-Sachs disease and other lyso-
somal storage disorders such as Fabry
disease will soon tell us if the initial
clinical results for pharmacological
chaperones [7] can be generalized. It
will be interesting to see if screening
for novel pharmacological chaperones
will become a common approach in
the search for conformational disease
treatments.
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Histone lysine methyltransferases, like G9a, play central roles in the regulation of gene expression. A
current study by Kubicek et al. [1] reports the identification of a G9a small-molecule inhibitor, thereby
opening the way to new epigenetic cancer therapies.An important part of the pathogenesis
of cancer lies in the inactivation of
tumor suppressor genes, which can
be achieved either genetically or epi-
genetically. Epigenetic alterations re-
fer to changes in gene expression
that do not result from alterations in242 Chemistry & Biology 14, March 2007the DNA sequence. Epigenetic mecha-
nisms include DNA methylation, and
histone protein acetylation and meth-
ylation. Both DNA methylation and
histone acetylation have been the tar-
get of small-molecule therapies [2, 3],
while the development of compoundsª2007 Elsevier Ltd All rights reservedthat target lysine and arginine methyl-
transferases has lagged behind. In a re-
cent issue of Molecular Cell, Kubicek
et al. [1] described screening for and
identification of a highly specific, small
molecular weight histone lysine meth-
yltransferase (HKMT) inhibitor that
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Previewsperturbs the levels of the histone H3 ly-
sine 9 dimethyl-mark (H3K9me2),
which is a signature of transcriptional
repression. The bunazosin-related
compound selectively inhibits the
HKMT G9a, but not the closely related
HKMT GLP. This compound also does
not inhibit the H3K9me3 HKMT
SUV39H1, the H3K9me1 HKMT
SET7/9, or the primary arginine methyl-
transferase PRMT1.
Global inhibitors of methylation do
exist and are used as research tools.
These include analogs of S-adenosyl-
methionine (AdoMet), the methyl do-
nor, like sinefungin and methylthioade-
nosine, and small molecules that inhibit
S-adenosyl-L-homocysteine (AdoHcy)
hydrolase like adenosine dialdehyde
(AdOx) and 3-deaza-neplanocin A
(DZNep), which cause intracellular ac-
cumulation of AdoHcy and feedback
inhibition of most methylation reac-
tions. These broad-spectrum inhibitors
lack the finesse of molecules that can
target the action of a single enzyme,
and are thus of limited utility in studies
on target biology or as leads for molec-
ularly targeted therapeutics. Recently,
high-throughput screens (HTS) were
performed to identify inhibitors of spe-
cific protein methyltransferases, in-
cluding PRMT1 [4] and SU(VAR)3-9
[5]. Although these studies identified
inhibitory molecules, in both cases
the HTS hits were not optimal. While
the identified arginine methyltransfer-
ase inhibitors (AMIs) did not inhibit
HKMTs, they lacked specificity within
the PRMT family (i.e., these AMIs in-
hibited all the PRMTs tested). The iso-
lated SU(VAR)3-9 inhibitor is a fungal
compound called chaetocin. Chaeto-
cin also inhibits a subset of other SET
domain-containing HKMTs, including
DIM5 and G9a, albeit at slightly higher
concentrations. Chaetocin can form
disulfide bonds with many intracellular
proteins, limiting its utility as a tool for
studying the biology of SU(VAR)3-9
[6]. In addition, it is a relatively large
molecule (MW = 696.84 Da), hence lim-
iting its potential for chemical optimiza-
tion toward SU(VAR)3-9 and other
HKMTs.
It is at this juncture that Kubicek et al.
[1] enter the picture with their screen for
G9a inhibitors, which would be ex-
pected to perturb the histone H3 lysine9 methylation states. They performed
an HTS with 125,000 compounds, pre-
selected on the basis of similarity to
a pharmacophore fingerprint built with
the AMI compounds [4]. The screen
used the N-terminal tail of histone H3
as a substrate and the SET domain
of G9a fused to GST as the enzyme.
The screen was performed at a high
AdoMet concentration (20 mM) to limit
the number of ‘‘hits’’ that would likely
be AdoMet competitive. AdoMet-
competitive compounds would most
likely inhibit other AdoMet-utilizing
enzymes, including DNA methyltrans-
ferases, isoprenylcysteine carboxyl-
methyltransferases, protein L-isoas-
partyl O-methyltransferases, and
PRMTs [7].
The discovery of a highly specific in-
hibitor, the bunazosin (a-adrenorecep-
tor antagonist) analog BIX-01294,
highlights the success of the screen
and the possibility that other existing
drugs and their analogs could hit the
HKMT family. A viable approach to
find drug-like inhibitors for other
HKMTs would thus be to screen for
HKMT side activities of such com-
pounds. Another identified inhibitor,
BIX-01338, was competitive with
AdoMet and inhibited several HKMTs
nonspecifically; however, it could still
potentially be amenable to chemical
optimization to hone selectivity toward
different HKMTs in a manner similar to
what has been achieved with ATP-
competitive inhibitors of kinases [8,
9]. Moreover, the dissociation en-
hanced lanthanide fluorescence im-
muno-assay (DELFIA) [10] format
used for G9a will be relatively easy to
replicate with other histone methyl-
transferases, provided the right pep-
tide substrate and matching methylly-
sine-specific antibody are utilized. An
isotopic assay format [11] and an
S-adenosylhomocysteine hydrolase-
coupled assay [12] have been reported
previously and are also generally
applicable to any protein methyltrans-
ferase.
A G9a small-molecule inhibitor is
clearly of pharmaceutical interest. G9a
and its homolog GLP were found to
copurify with the transcriptional core-
pressor protein CtBP [13]. That same
study showed that siRNA knockdown
of CtBP, G9a, or GLP resulted in upre-Chemistry & Biology 14, March 2007 ªgulation of E-cadherin in cancer cells
where this gene was epigenetically
downregulated. Downregulation of E-
cadherin and other epithelial genes
by transcriptional repressors, such as
ZEB1 and ZEB2, that recruit CtBP
and G9a/GLP is a hallmark of the epi-
thelial-mesenchymal transition that
underlies the progression of cancer
to metastasis [14]. Moreover G9a has
been implicated in the function of
CutL1 [15]. CutL1 is a transcription
factor that activates a transcriptional
program regulating genes involved in
cell motility, invasion, and extracellular
matrix composition downstream of
TGFbeta signaling [16]. Chemical in-
hibitors of G9a could thus potentially
contribute to upregulation of E-cad-
herin and attenuation of CutL1 func-
tion with the hopes of impeding the
shift to metastasis.
Many other HKMTs have been
linked to human disease and could
serve as promising targets for small-
molecule drug therapy. Such is the
case with EZH2, a histone H3 lysine
27 HKMT overexpressed in many ag-
gressive cancers where it is predictive
of poor outcome [17]. Inhibition of
EZH2 by siRNA has been shown to
prevent metastasis of PC-3 prostate
cancer cells in mice [18]. Moreover,
there is accumulating evidence to
implicate HKMTs such as Smyd3,
SETDB1, NSD1, NSD2, NSD3, and
Suv39h1 in human cancers [19, 20].
The discovery of a small molecule
that can specifically inhibit G9a is
a great accomplishment, which shows
for the first time that this class of epi-
genetic regulator is a viable target for
drug development efforts. Similar
screens to that conducted by Thomas
Jenuwein’s group [1] could be used to
identify small-molecule inhibitors for
other HKMTs and hence herald a
promising new wave of molecularly
targeted therapeutics for cancer and
other diseases. Such agents would
also increase the arsenal for combina-
tion with existing epigenetic (HDAC
and DNMT inhibitors) and signal trans-
duction drugs (e.g., kinase inhibitors).
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